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Abstract 
Two novel core-switching rearrangements to natural product-like privileged scaffolds 
that proceed in up to 99% yield have been developed. The deviation away from 
planarity of the central N-acyl urea carbonyl, caused by the structure of the medium-
sized ring, dictates the exclusive reaction outcome. Proposed mechanisms and 
products for the reaction pathways are supported by small molecule X-ray 
crystallography and an isolated intermediate. Twenty-four novel rearrangement 
products are reported. 
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Introduction 
Rearrangements are of central importance in organic synthesis allowing remarkable 
and efficient transformations of simple starting materials to complex products in one 
pot.1 In particular, rearrangements that give difficult to access ring sizes and ring 
fusions are much sought after.2 As part of a discovery programme, we explored the 
reactivity and chemistry of nine and ten-membered N-acyl cyclic ureas towards 
nitrogen-containing heterocyclic rearrangement chemistry.3 Pyrrolo[2,3-b]quinolines 
and fused diazocines such as diazocino[1,2-a]indolinones are important nitrogen-
containing heterocycles prevalent in natural products and pharmaceuticals. The 
pyrrolo[2,3-b]quinoline is a privileged scaffold found in biologically important 
molecules such as blebbistatin (a myosin II inhibitor, Figure 1A)4 and PGP-4008 (as a 
selective P-glycoprotein (P-gp) mediated drug release (MDR) modulator).5 The 
diazocino and fused diazocino scaffold can be found in natural products such as the 
sperimidine derived alkaloids,6 peptidomimetic scaffolds,7 in SM-406/AT-406 (Figure 
1A) an inhibitor of proteins involved in apoptosis8 and small-molecule mimetics of 
second mitochondria-derived activator of caspases (Smac).9 The α-hydroxyindolinone 
unit is present in the natural products matemone10 and melochicorine.11 In particular, 
matemone inhibits cell division (IC50 = 35 µg mL-1) and showed moderate activity 
against three cancer cell lines (lung, pancreas and prostate) and antibacterial activity 
against S. Aureus.  
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Figure 1A Representative bioactive small molecules containing motifs present in 2 
and 3. 1B The rearrangement of 1 to diazocino[1,2-a]indolinone 2 and pyrrolo[2,3-
b]quinoline 3. 
 
Our recent studies with compounds related to type 112 (Figure 1B) have demonstrated 
the unusual properties associated with these atropisomeric medium-ring systems. 
Compounds of type 1 can be accessed rapidly via pentacyclic ring fusion from N-aryl 
lactams and anthranilates13 followed by m-CPBA mediated Grob fragmentation.14 
Herein, we report the rearrangement chemistry associated with 9 and 10-membered 
examples of 1 to access privileged diazocino[1,2-a]indolinones 2 and pyrrolo[2,3-
b]quinolines 3. 
 
Results and Discussion 
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During the detailed NMR spectroscopic experiments involved with understanding the 
atropisomeric nature of 1a,14 it was found that 1a in d4-methanol upon standing 
transformed quantitatively into a new product. This reaction could be replicated using 
sodium methoxide in methanol. X-ray crystallographic analysis of the crystals obtained 
revealed the structure as 2a (Scheme 1).15,16  
 
 
Scheme 1. Plausible reaction pathway for the formation of 2a from 1a and a 
representation of the small molecule X-ray crystallographic analysis of 2a. Reaction 
conditions: NaOMe, MeOH, 25 oC, 10 min, 99%. 
 
A proposed mechanism for the rearrangement of 1a is shown in Scheme 1. The key 
step in this transformation was attack of the nucleophile at the C(16) carbonyl group 
of 1a to afford A. It is proposed that cyclisation of A furnishes the more 
thermodynamically stable 2a. Ureas are typically quite poor electrophiles, so it was 
initially surprising that a reaction took place at this functionality. However, the C(16) 
carbonyl group is tilted out of the plane contains the two nitrogens (N(6) and N(15)) 
and the C(1) carbonyl group (the X-ray crystal structure of 1a can be found at CCDC-
804714).14 The key dihedral angle for 1a C(14a)-N(15)-C(16)-O(16) is +25o. 
Therefore, the C(16) carbonyl group would be more reactive than expected to 
nucleophilic attack. The non-planarity of the urea has the effect of lessening the 
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electron donation into the π* orbital of the C(16) carbonyl group and hence increasing 
the electrophilicity of the urea carbonyl group. On simpler substrates there have been 
examples of oxidative cleavage and nucleophile induced rearrangement17 not driven 
by carbonyl group distortion. Consistent with the proposed mechanism, reaction of an 
optically-enriched sample of 1a with sodium methoxide gave a racemic sample of 2a 
(see Scheme S1 for a more detailed discussion).15 A screen of nucleophiles that could 
potentially replicate this transformation was also carried out (Table S1).15 The scope 
of this rearrangement was determined by screening a collection of nine-membered N-
acyl cyclic ureas 1 (Table 1) with different alkoxides using optimised conditions (Table 
S2) and subsequently amines (optimised conditions detailed in Table S3).15 
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Table 1. Examples of O and N-centred nucleophile-induced rearrangement of the 
nine-membered ring system to (±)-2 and a representation of the small molecule X-
ray crystallographic analysis of 2i. aReaction conditions: 1 (0.06 mmol), NaOR (0.13 
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mmol), ROH (2 mL), 25 oC, 10 min. bReaction conditions: 1 (0.06 mmol), RNH2 (0.06 
mmol), THF (3 mL), 25 oC, 3h. cAll isolated yields. 
 
It was observed that the alkoxide-induced rearrangement was general on a selection 
of nine-membered substrates (1a-1d).14 Almost all alkoxide-induced rearrangments 
proceeded in nearly quantitative yield at ambient temperature and with short reaction 
times and the products could be easily purified either by column chromatography or 
recrystallisation.  
The amine-induced rearrangements proceeded in similar high conversions as 
determined by 1H NMR analysis of the crude reaction mixture.15 However, a significant 
reduction in isolated yield was observed across examples 2i-2o. This was due to the 
polar nature of the installed N, N’-substituted urea leading to difficulties in elution. 
Conclusive evidence that the amine-induced rearrangement afford the analogous 5,8-
ring system was obtained via the small molecule X-ray crystallographic analysis of 2i 
(Table 1).15,16  
With the successful synthesis of the azepinoindole (5,8)-ring system 2 by 
rearrangement of the N-acyl cyclic ureas 1a-d (nine-membered), it was decided to 
investigate whether the ten-membered N-acyl cyclic ureas 1e-f14 would undergo a 
similar rearrangement to generate the azepinoindole (5,9)-ring system. Treatment of 
1e with sodium methoxide in anhydrous methanol did not afford the expected 5,9-ring 
system (2p), instead a pyrrolo[2,3-b]quinoline 3a was obtained exclusively (Scheme 
2). 
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Scheme 2. Formation of a pyrrolo[2,3-b]quinoline 3a from 1e and no observation of 
2p. 
 
It is proposed that enolisation of the α-diketone in 1e with sodium methoxide acting as 
a base would lead to the formation of products containing a pyrrolidine ring system in 
3 from attack of the C9 enolate at the C(17) carbonyl group (see Scheme 3 for 
mechanistic discussion in the context of the reaction of 1g).  
The small molecule X-ray crystallographic analysis of 1e also provided interesting 
information.14 The key dihedral angle (C(15a)-N(16)-C(17)-O(17)) was closer to 
planarity in the ten-membered 1e at +14o 18 (c.f. +25o in the nine-membered 1a). This 
implies the C(17) carbonyl is less electrophilic and direct reaction with sodium 
methoxide leading to a ring-opened structure is less favoured. Enolisation at C8 
(Scheme 1) could operate in the nine-membered ring system (such as 1a) but would 
be unproductive as a highly strained 4-membered ring would result from attack at the 
analogous C(16) carbonyl group.  
The postulated mechanism for the formation of the pyrrolo[2,3-b]quinoline (Scheme 3) 
was supported when substrate 1g was used in this reaction. In this case it was found 
that only trace quantities of the now expected pyrrolo[2,3-b]quinoline 3d (Table 3) was 
isolated. Elucidation of the structure of the major isolated product 4 (Scheme 3) was 
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achieved by 1H, 13C and 2D-NMR experiments (1H-13C HSQC, 1H-13C HMBC and 1H-
13C COSY NMR spectra).15 The tabulated 1H and 13C NMR assignments relating to 4 
are shown in Table S4.15 
Key points in the structural determination of 4 included the signals corresponding to 
the C2-H2 and C3-H2 protons being observed as a pair of triplets indicating a five 
membered ring had formed as the C(9) protons in 1g had disappeared (Scheme 3). 
The 1H-13C HMBC NMR spectrum of 4 was used to determine the location of the single 
ethyl ester, which indicated that it was connected to ring D. Furthermore, the 1H and 
13C NMR shifts on the protons and carbons, in ring D of 4 were analogous with those 
present in 3d. A broad singlet in the 1H NMR spectra indicated that an exchangeable 
proton i.e. OH or NH existed. Due to the 13C chemical shifts of the C(9) (134.7 ppm) 
and C(9a) (148.6 ppm) carbons in 4 an NH motif was ruled out because, if present, 
this would have the effect of moving the chemical shifts in ring A upfield (which was 
not seen). Furthermore, infra-red spectroscopy indicated the presence of an intra-
molecular H-bond at 2977 cm-1. The enol form of the aza-tropinone in 4 is the preferred 
tautomer of the ring system and similar examples have been reported.19 The structure 
of ring B in 4 could now be assigned using a 1H-13C HMBC NMR experiment (Scheme 
3, inset). A correlation was observed between the C3, 6 and 9 protons with the C5 
carbonyl carbon. Similarly, a correlation was observed between the C3 protons and 
the C4 carbon. 
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Scheme 3. Plausible reaction pathways a and b for the formation of 3d from 1g via 
isolated intermediate 4 and selected 1H-13C HMBC NMR spectrum correlations of 4 
that were used to determine the structure of ring B (red 3 bond, blue 4 bond 
correlations). 
 
The structure 4 can be viewed as the intermediate immediately prior to the formation 
of intermediate C via pathway A or intermediate E via pathway B (Scheme 3). Pathway 
A, a benzylic rearrangement20 of 4 is likely due to non-enolizable diketone functionality 
present and in particular, the highly electrophilic C5 carbonyl group ( 178.3 ppm, 13C 
NMR). Therefore, attack of ethoxide at the C5 position of C could induce a ring 
contraction via D to 3d. Pathway B, a quasi-Favorksii rearrangement21 proceeding via 
cyclisation of the N(10) enamine onto the C(5) carbonyl group will form a strained 
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cyclopropanone (intermediate E). The cyclopropanone E will be labile to attack by 
alkoxide and in doing so the ring strain will be relieved. Elimination of hydroxide from 
E will generate an aromatic quinoline ring (c.f. Camps quinolinol synthesis22). In favour 
of pathway B is recent work by Karimi23 which details an oxidative Favorskii 
rearrangement of an aryl fused seven-membered ring which contracts invoking a 
cyclopropanone intermediate to a six-membered ring system. This type of ring 
contraction of seven to six-ring systems has previously been reported.24  
In this unexpected reaction of ten-membered examples of N-acyl cyclic ureas 1 (1e-
1h) a series of steps occur in concert to generate a 2,3-dihydro-1H-pyrrolo[2,3-
b]quinoline 3, the driving force being presumably the generation of an extended 
aromatic system. When 4 was re-submitted to the reaction conditions 3d was 
obtained. Intermediates of structural type 4 were not isolated and characterised from 
other alkoxide or amine-induced rearrangements to 3. Further evidence for the 
presence of intermediates analogous to 4 was provided by 1H NMR analysis of the 
NaOMe reaction with 1g which provided evidence of a similar intermediate (containing 
one methyl carboxylate group) but in insufficient quantity for a full assignment (trace < 
5%, data not shown). 
The alkoxide-induced rearrangement of 1 to 3 required little optimization (Table S5).15 
The initial reaction conditions proved robust, with good isolated yields after column 
chromatography. Attempts to push the reaction further by heating at reflux overnight 
led to a reduced yield alongside apparent degradation of the product. Addition of extra 
equivalents of alkoxide also failed to improve the reaction yield. Attempts to optimise 
the amine-induced rearrangement of 1e required more study (Table 2). The 
percentage conversion improved by refluxing the reaction mixture in higher boiling 
point solvents. It was also noted that using a 10-fold excess of the amine improved the 
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yield of the reaction but only modest improvements in conversion (and isolated yield) 
were observed. 
Changing to microwave irradiation allowed for a dramatic reduction in reaction time. 
Low power usage using a commercially available microwave (100 W, entry 6) gave 
the first indication that the reaction conversion could be improved. Higher power usage 
(200 W, entry 7) led to degradation. A refinement of this approach allowed for the 
removal of the need for solvent. Instead, the addition of 10 equivalents of the amine 
to 1e formed a slurry which allowed the reaction to proceed. The percentage 
conversion measured by 1H NMR analysis of the crude reaction mixture indicated that 
almost complete consumption of the starting material had occurred when using 150 W 
(entries 8 and 9). After column chromatography the isolated yield for 3a was an 
acceptable 58%. 
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Entry 
Nucleophile 
(eq.) 
Solvent 
Temperature 
(oC) 
Time 
(h) 
% Conversion 
1 2 DCM 25 48 <10 
2 10 DCM 25 168 31 (20a) 
3 2 THF 25 48 <10 
4 10 THF 66 48 54 (36a) 
5 10 DCE 84 48 80 (48a) 
6 10 No solvent 80 (100 W) 10 min 50 
7 10 No solvent 80 (200 W) 10 min Degradation 
8 10 No solvent 80 (150 W) 10 min 95 (58a) 
9 10 No solvent 80 (150 W) 5 min 95 (58a) 
Table 2. Optimisation Studies on the Synthesis of 3e from 1e.aIndicates isolated yield 
obtained by flash column chromatography. 
 
To explore if the pyrrolo[2,3-b]quinoline reaction was general, a series of ten-
membered N-acyl cyclic ureas 1e-1h were subjected to alkoxide or amine-induced 
rearrangement using the optimised conditions in either a commercially available 
microwave reactor or a Radleys® Greenhouse parallel synthesiser. The results of 
these experiments are detailed in Table 3. 
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Table 3. Examples of O and N-centred nucleophile-induced rearrangement of the 
ten-membered ring system. aReaction conditions: 1 (0.06 mmol), NaOR (0.12 mmol), 
ROH (2 mL), 25 oC, 16 h. bReaction conditions: 1 (0.06 mmol), RNH2 (0.6 mmol), mw 
80 oC (150 W), 5 min. c All isolated yields. dConcomitant isolation of 4 (40% isolated 
yield) from the same reaction as 3d.  
The alkoxide-induced rearrangement proceeded in modest to good yields (3a-3c), the 
noticeable exception being 3d which was afforded in a 7% yield but delivered the 
isolated intermediate 4 in 40% yield and informed additional mechanistic 
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understanding of this reaction. A trend regarding the steric requirements of the 
alkoxides was identified. Using a secondary alkoxide (sodium isopropoxide) prevented 
the rearrangement occurring (3i-3l) and led to the recovery of the starting material (1e-
1h). 
Similarly, to the azepinoindole rearrangement in the nine-membered N-acyl cyclic urea 
series the incorporation of an amine-based nucleophile could be optimised for high 
conversions (Table 2) but the resulting isolated yield after column chromatography 
was reduced due to the polar character of the double amide-containing product that 
was formed (Table 3). Therefore, trends regarding amine nucleophiles were more 
difficult to rationalise due to the isolation method employed. Further examples of 
related structural analogues of the two rearrangements are in biological evaluation 
and will be reported in due course. 
Conclusion 
In summary, we have developed a selective, one-pot syntheses of diazocino[1,2-
a]indolinones and pyrrolo[2,3-b]quinolines from readily accessed starting materials. 
Assignment of the products from these rearrangements was derived from X-ray crystal 
structure evidence and advanced NMR spectroscopic techniques. In the ring-enlarged 
N-acyl cyclic urea series a rearrangement was observed to afford pyrrolo[2,3-
b]quinoline 3. The mechanism of the pyrrolo[2,3-b]quinoline reaction in the 10-
membered N-acyl cyclic urea series was elucidated by the isolation of a reaction 
intermediate 4.  
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Experimental Section 
General Methods. Unless otherwise noted, all the commercial reagents were used 
without further purification. All reactions involving moisture sensitive reagents were 
performed in oven dried glassware under a positive pressure of argon. 
Tetrahydrofuran (THF), dichloromethane (DCM) and toluene were obtained dry from 
a solvent purification system (MBraun, SPS-800). Alcohols used for the formation of 
alkoxides were dried either by standing over 4Å molecular sieves or by distillation from 
barium oxide under an argon atmosphere. N,N’-dimethylenediamine (DMED), 
triethylamine and triisopropylamine were all dried by distillation from KOH. Thin-layer 
chromatography was performed using glassplates coated with silica gel (with 
fluorescent indicator UV254) (Aldrich). Developed plates were air-dried and analysed 
under a UV lamp. Flash column chromatography was performed using silica gel (40-
63 m) (Fluorochem). Melting points were recorded in open capillaries using an 
Electrothermal 9100 melting point apparatus. Values are quoted to the nearest 1 oC 
and are uncorrected. Elemental microanalyses were performed on a Carlo Erba CHNS 
analyser within the School of Chemistry at the University of St Andrews. Infrared 
spectra were recorded on a Perkin Elmer Spectrum GX FT-IR spectrometer using 
either thin films on NaCl plates (NaCl) or KBr discs (KBr) as stated. Absorption maxima 
are reported as wavenumbers (cm-1) and intensities are quoted as strong (s), medium 
(m), weak (w) and broad (br). Low resolution (LR) and high resolution (HR) 
electrospray mass spectral (ES-MS) analyses were acquired by electrospray 
ionisation (ESI), electron impact (EI) or chemical ionisation (CI) within the School of 
Chemistry, University of St Andrews. Low and high resolution ESI MS were carried out 
on a Micromass LCT spectrometer and low and high resolution CI MS were carried 
out on a Micromass GCT spectrometer recorded on a high performance orthogonal 
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acceleration reflecting TOF mass spectrometer, coupled to a Waters 2975 HPLC. Only 
the major peaks are reported and intensities are quoted as percentages of the base 
peak. The purity of compounds was measured using liquid chromatography mass 
spectrometry (LCMS). The LCMS system includes a Waters 2996 photodiode array 
detector, Waters 2795 Alliance HT Separations Module, Micromass LCT, Thinkcenter 
IBM running MassLynxTM 4.0.Global. Separations were performed using a Waters 
XterraTM RP18 (5µm, 3.0 x 50 mm) HPLC column. Nuclear magnetic resonance (NMR) 
spectra were acquired on either a Bruker Avance 300 (1H, 300.1 MHz; 13C, 75.5 MHz), 
Bruker Avance 400 (1H, 400 MHz; 13C, 100.1 MHz) or a Bruker Avance 500 (1H, 500 
MHz; 13C, 125 MHz) spectrometer and in the deuterated solvent stated. 13C NMR 
spectra were acquired using the PENDANT or DEPTQ pulse sequences. All NMR 
spectra were acquired using the deuterated solvent as the lock. Coupling constants 
(J) are quoted in Hz and are recorded to the nearest 0.1 Hz. The following 
abbreviations are used; s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of 
doublets of doublets; dt, doublet of triplets; t, triplet; m, multiplet; q, quartet; qt, quintet; 
and br, broad. Microwave assisted reactions were performed using a CEM Discover 
microwave operated in ‘powermax’ mode. The synthesis and characterisation of 
compounds 1a, 1c, 1d, 1e, 1f, 1g, 1h, 1i have been reported elsewhere.14  
Spectroscopic Data. 
12-Pentyloxy-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-
tetrone (1b): 5-hydroxy methyl anthranilate (4.0 g, 23.9 mmol), 1-pentanol (3.9 mL, 
35.9 mmol) and triphenylphosphine (9.4 g, 35.9 mmol) were dissolved in anhydrous 
tetrahydrofuran (40 mL) to which was added diethylazodicarboxylate (5.7 mL, 35.9 
mmol) and stirred at room temperature for 72 h. The reaction mixture was washed with 
2.0 M NaOH (2 x 50 mL), water (100 mL) and the aqueous layer extracted with ethyl 
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acetate (3 x 50 mL). The organic phase was dried (MgSO4), filtered and concentrated 
in vacuo to give a brown oil which was purified by flash column chromatography on 
silica gel (1:10, ethyl acetate:hexane) to afford Methyl 2-amino-5-(pentyloxy)benzoate 
(5.62 g, 23.7 mmol, 99%) as a brown oil. 1H NMR (300 MHz, CDCl3):  7.35 (d, 4J = 
3.0 Hz, 1H, C6-H), 6.95 (dd, 3J = 9.0 Hz, 4J = 3.0 Hz, 1H, C4-H), 6.62 (d, 3J = 9.0 Hz, 
1H, C3-H), 5.39 (s, 2H, NH2), 3.89 (t, 3J = 6.5 Hz, 2H, OCH2) 3.87 (s, 3H, CO2CH3), 
1.82-1.70 (m, 2H, OCH2CH2), 1.49-1.32 (m, 4H, CH2CH2CH3), 0.93 (t, 3J = 7.0 Hz, 3H, 
CH3); 13C NMR (75.5 MHz, CDCl3):  168.7 (CO2Me), 150.4 (C5), 145.5 (C2), 124.2 
(C4), 118.6 (C3), 114.7 (C6), 111.1 (C1), 69.2 (OCH2), 52.0 (CO2CH3), 29.5 
(OCH2CH2), 28.6 (CH2CH2CH3), 22.9 (CH2CH2CH3), 14.4 (CH3); IR (KBr): max = 3478 
(m) (NH2), 3370 (m), 2956 (s), 2872 (m), 1699 (s) (C=O), 1565 (m), 1497 (s), 1288 (s), 
1221 (m), 1154 (w) (C-O), 1096 (w), 740 (m) (Ar-H) cm-1; LRMS (ES+): m/z (%) 238.21 
(100) [M+H]+, 260.17 (90) [M+Na]+; HRMS (ES+): m/z calcd for C13H19NO3Na [M+Na]+: 
260.1263; found 260.1268. 10-Pentyloxy-8,14-dioxo-6,7-dihydro-8H,14H-5,13-
diazabenz[e]aceanthrylene (0.23 g, 0.63 mmol, 63%) was afforded as a yellow powder 
using the general procedure reported.13 Briefly, A mixture of the methyl anthranilate 
(4.0 mmol, 4.0 eq.) and N-aryl lactam (1.0 mmol, 1.0 eq.) in a sealed glass microwave 
tube was heated to 190 oC, (maximum 275 W), with air flowing through the reaction 
chamber, for 30 minutes. Upon cooling the reaction mixture was added to diethyl ether 
(30 mL) and the resultant precipitate filtered. The precipitate was purified by flash 
column chromatography over silica gel (99:1, chloroform:methanol) to afford the title 
compound. An analytically pure sample was prepared by recrystallisation from acetic 
acid. Mp 264 oC (dec.); 1H NMR (300 MHz, CDCl3):  9.42 (d, 3J = 9.5 Hz, 1H, C12-
H), 8.24 (dd, 3J = 8.0 Hz, 4J = 1.5 Hz, 1H, C1-H), 7.84 (d, 4J = 3.0 Hz, 1H, C9-H), 7.68 
(ddd, 3J = 8.0 Hz, 3J = 8.0 Hz, 4J = 1.5 Hz, 1H, C3-H), 7.22 (ddd, 3J = 8.0 Hz, 3J = 8.0 
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Hz, 4J = 1.0 Hz, 1H, C2-H), 7.15 (dd, 3J = 9.5 Hz, 4J = 3.0 Hz, 1H, C11-H), 6.93 (d, 3J 
= 8.0 Hz, 1H, C4-H), 4.28 (t, 3J = 9.0 Hz, 2H, C6-H2), 4.05 (t, 3J = 6.5 Hz, 2H, OCH2), 
3.36 (t, 3J = 9.0 Hz, 2H, C7-H2), 1.89-1.78 (m, 2H, OCH2CH2), 1.54-1.37 (m, 4H, 
CH2CH2CH3), 0.96 (t, 3J = 7.0 Hz, 3H, CH3); 13C NMR (75.5 MHz, CDCl3):  172.1 
(C8), 159.7 (C14), 157.3 (C10), 148.0 (C5a), 138.5 (C4a), 135.8 (C3), 130.1 (C12a), 
129.9 (C1), 129.4 (C8a), 122.6 (C12), 122.4 (C2), 119.4 (C11), 114.5 (C14a), 112.1 
(C4), 107.0 (C9), 101.9 (C7a), 68.3 (OCH2), 47.3 (C6), 28.9 (OCH2CH2), 28.2 
(CH2CH2CH3), 23.4 (C7), 22.5 (CH2CH2CH3), 14.0 (CH3); IR (KBr): max = 2953 (s) 
(OCH2), 2933 (s) (OCH2), 2870 (s) (OCH2), 1700 (s) (C=O), 1630 (s) (NHCO), 1585 
(m), 1558 (m), 1351 (m), 1288 (s) (C-O), 1172 (m) cm-1; LRMS (ES+): m/z (%) 375.17 
(100) [M+H]+, 374.16 (45) [M]+; HRMS (ES+): m/z calcd for C23H23N2O3 [M+H]+: 
375.1709; found 375.1706. Using the Büchi Syncore parallel reaction apparatus the 
following procedure was performed.14 To a suspension of the 
diazabenz[e]aceanthrylene (1.0 mmol, 1.0 eq.) in anhydrous chloroform (15 mL) was 
added purified m-CPBA (2.5 mmol, 2.5 eq.) portion-wise. The reaction mixtures were 
shaken at room temperature for 16 hours and then added NaHCO3(aq.) (10 mL) and 
extracted with dichloromethane (3 x 10 mL). The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo to give a solid which was purified by dry-flash 
column chromatography over silica gel (3:7, ethyl acetate:hexane) furnished the title 
compound. Recrystallisation from acetone afforded an analytically pure sample of 12-
Pentyloxy-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-
tetrone,1b (0.17 g, 0.41 mmol, 41%) was afforded as a pale grey powder. Mp 58-59 
oC; 1H NMR (300 MHz, CDCl3):  8.20 (dd, 3J = 8.0 Hz, 4J = 1.0 Hz, 1H, C2-H), 7.76-
7.71 (m, 1H, C4-H), 7.63-7.55 (m, 2H, C14-H, C11-H), 7.34-7.22 (m, 3H, C5-H, C3-H, 
C13-H), 4.84-4.76 (m, 1H, C7-Ha), 4.40-4.32 (m, 1H, C7-Hb), 4.10-3.98 (m, 2H, OCH2), 
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3.85-3.76 (m, 1H, C8-Ha), 2.93-2.85 (m, 1H, C8-Hb), 1.88-1.78 (m, 2H, OCH2CH2), 
1.51-1.35 (m, 4H, CH2CH2CH3), 0.95 (t, 3J = 7.0 Hz, 3H, CH3); 13C NMR (75.5 MHz, 
CDCl3):  199.0 (C9), 190.9 (C10), 160.6 (C1), 159.1 (C12), 155.8 (C16), 141.5 (C5a), 
135.9 (C4), 131.2 (C10a), 130.9 (C14), 129.7 (C2), 129.1 (C14a), 124.4 (C5), 120.0 
(C13), 116.7 (C1a), 116.6 (C11), 115.9 (C3), 68.8 (OCH2), 44.8 (C7), 35.9 (C8), 28.9 
(OCH2CH2), 28.2 (CH2CH2CH3), 22.5 (CH2CH2CH3), 14.5 (CH3); IR (KBr): max = 2923 
(m), 1715 (s), 1669 (s), 1609 (s), 1575 (m), 1477 (m), 1386 (m), 1162 (m), 757 (m) cm-
1; LRMS (ES+): m/z (%) 429.14 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C23H22N2O5Na [M+Na]+: 429.1426; found 429.1424. 
Typical Procedure for the Synthesis of 2. 
Alkoxide nucleophiles: Reactions were conducted in parallel using the Radleys 
Greenhouse Parallel synthesiser. To a solution of the N-acyl cyclic urea 1 (0.06 mmol, 
1.0 eq.) in the respective anhydrous alcohol (methanol or ethanol) (2 ml) was added 
the respective sodium alkoxide (sodium methoxide or sodium ethoxide) (0.13 mmol, 2 
eq.). The reaction mixture was stirred at room temperature for 10 min and then 
evaporated in parallel, re-dissolved in dichloromethane (2 x 4.0 mL) and washed with 
NaHCO3(aq.) (2 x 2.0 mL). The mixtures were passed through an IsoluteTM phase 
separator and the organic layer was dried (Na2SO4 cartridge) and concentrated in 
vacuo to give a solid which was purified by recrystallisation from ethyl acetate/hexane 
to afford the title compound. 
Amine nucleophiles: Reactions were conducted in parallel using the Radleys 
Greenhouse Parallel synthesiser. To a solution of the N-acyl cyclic urea 1 (0.06 mmol, 
1.0 eq.) in anhydrous tetrahydrofuran (3 ml) was added the amine ((0.20 M n-
butylamine, benzylamine used as received from Aldrich, 0.23 M 
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aminomethylcyclopropane, 0.23 M 2-methoxyethylamine, or 0.15 M 4-(2-
aminoethyl)morpholine) from a freshly prepared stock solution in anhydrous 
tetrahydrofuran) (0.06 mmol, 1.0 eq.). The reaction mixture was stirred at room 
temperature for 3 h. The reaction mixtures were evaporated in parallel to give a solid 
which was purified by recrystallisation from ethyl acetate/hexane to afford the title 
compound. 
8-Methyl carboxylate-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-diazocin-
5,13-dione (2a)15,16: white powder (22 mg, 99%), mp 226-227 oC; 1H NMR (300 MHz, 
CDCl3):  8.37 (d, 3J = 8.5 Hz, 1H, C1-H), 7.77-7.71 (m, 2H, C2-H, C4-H), 7.58-7.51 
(m, 2H, C12-H, C10-H), 7.45-7.39 (m, 1H, C11-H), 7.30-7.19 (m, 2H, C3-H, C9-H), 
4.23 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 3.59 (s, 3H, CO2CH3), 3.65-3.51 (m, 
1H, C7-Hb), 2.38-2.27 (m, 1H, C6-Ha), 1.75 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb); 
13C NMR (75.5 MHz, CDCl3):  199.1 (C5), 166.5 (C13), 155.4 (CO2Me), 151.7 (C14a), 
138.1 (C2), 138.0 (C8a), 136.6 (C12a), 132.0 (C10), 129.2 (C12), 128.4 (C11), 128.0 
(C9), 125.2 (C3), 124.5 (C4), 121.2 (C4a), 120.2 (C1), 90.3 (C5a), 53.2 (CH3) 44.9 
(C7), 33.9 (C6); IR (KBr): max = 3285 (s), 2994 (m), 2957 (m), 1732 (s), 1674 (s), 1601 
(m), 1468 (m), 1371 (m), 1027 (m), 759 (m) cm-1; LRMS (ES+): m/z (%) 374.97 (100) 
[M+Na]+; HRMS (ES+): m/z calcd for C19H16N2O5Na [M+Na]+: 375.0957; found 
375.0946; An analytical sample of 2a was prepared by recrystallisation from 
EtOAc/hexane; Anal. calcd for C19H16N2O5: C, 64.77; H, 4.58; N, 7.95; found: C, 64.76; 
H, 4.24; N, 7.54. 
8-(Methyl carboxylate)-3-pentyloxy-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-
8,14-diazocin-5,13-dione (2b): White powder (22 mg, 99%); 1H NMR (300 MHz, 
CDCl3): δ = 8.22 (d, 3J = 9.0 Hz, 1H, C1-H), 7.51 (ddd, 3J = 7.7 Hz, 3J = 7.7 Hz, 4J = 
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1.4 Hz, 1H, C10-H), 7.48-7.43 (m, 1H, C12-H), 7.38-7.32 (m, 1H, C11-H), 7.27 (dd, 3J 
= 9.0 Hz, 4J = 3.0 Hz, 1H, C2-H), 7.18 (d, 3J = 7.7 Hz, 1H, C9-H), 7.02 (d, 4J = 3.0 Hz, 
1H, C4-H), 4.21 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 3.96 (t, 3J = 6.5 Hz, 2H, 
OCH2), 3.56 (s, 3H, OCH3), 3.47 (ddd, 2J = 13.0 Hz, 3J = 12.0 Hz, 3J = 4.0 Hz, 1H, C7-
Hb), 2.26 (ddd, 2J = 13.0 Hz, 3J = 12.0 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 1.82 (qt, 3J = 6.5 
Hz, 3J = 6.5 Hz, 2H, OCH2CH2), 1.72 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.52-
1.35 (m, 4H, CH2CH2CH3), 0.97 (t, 3J = 6.5 Hz, 3H, CH2CH3); 13C NMR (75.5 MHz, 
CDCl3):  199.6 (C5), 166.0 (C13), 156.8 (C3), 155.5 (CO2Me), 146.3 (C14a), 138.3 
(C8a), 136.8 (C12a), 132.0 (C10), 129.5 (C12), 128.6 (C11), 128.1 (C9), 127.6 (C2), 
122.1 (C4a), 121.5 (C1), 105.9 (C4), 90.7 (C5a), 68.8 (OCH2R), 53.3 (OCH3), 45.1 
(C7), 34.3 (C6), 28.9 (OCH2CH2R), 28.3 (OCH2CH2CH2R), 22.6 (CH2CH3), 14.2 
(CH2CH3); IR (NaCl): max = 2956 (m), 2929 (m), 2858 (m), 1714 (s) (C=O), 1647 (s) 
(C=O), 1619 (m), 1489 (m), 1458 (m), 1029 (w), 766 (w) cm-1; LRMS (ES+): m/z (%) 
461.02 (100) [M+Na]+; HRMS (ES+): m/z calcd for C24H26N2O6Na [M+Na]+: 461.1689; 
found 461.1689. 
3-Methyl-8-(methyl carboxylate)-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2c): White powder (22 mg, 99%), mp 99-100 oC; 1H NMR (300 
MHz, CDCl3):  8.31 (d, 3J = 9.0 Hz, 1H, C1-H), 7.61-7.52 (m, 4H, C4-H, C10-H, C12-
H, C2-H), 7.45 (ddd, 3J = 7.5 Hz, 4J = 1.5 Hz, 1H, C11-H), 7.24-7.19 (m, 1H, C9-H), 
4.32-4.22 (m, 1H, C7-Ha), 3.61 (s, 3H, CO2CH3), 3.55-3.45 (m, 1H, C7-Hb), 2.42 (s, 
3H, Ar-CH3), 2.41-2.31 (m, 1H, C6-Ha), 1.80-1.72 (m, 1H, C6-Hb); 13C NMR (75.5 MHz, 
CDCl3):  199.5 (C5), 166.4 (C13), 155.4 (CO2Me), 149.7 (C14a), 139.3 (C2), 138.2 
(C8a), 136.7 (C12a), 135.4 (C3), 132.0 (C10), 129.3 (C12), 128.5 (C11), 128.0 (C9), 
124.1 (C4), 121.4 (C4a), 120.0 (C1), 90.8 (C5a), 53.2 (OCH3), 45.0 (C7), 34.0 (C6), 
21.0 (ArCH3); IR (KBr): max = 3449 (br s), 1735 (s) (C=O), 1655 (s) (C=O), 1382 (m) 
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cm-1; LRMS (ES+): m/z (%) 388.99 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C20H18N2O5Na [M+Na]+: 389.1113; found 389.1110. 
2-Chloro-8-(methyl carboxylate)-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2d): White powder (22 mg, 99%), mp 93-94 oC; 1H NMR (300 
MHz, CDCl3):  8.46 (d, 4J = 1.5 Hz, 1H, C1-H), 7.69 (d, 3J = 8.0 Hz, 1H, C4-H), 7.58-
7.54 (m, 2H, C10-H, C12-H), 7.48-7.42 (m, 1H, C11-H), 7.28-7.20 (m, 2H, C3-H, C9-
H), 4.23 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 3.61 (s, 3H, CO2CH3), 3.54-3.44 
(m, 1H, C7-Hb), 2.41-2.30 (m, 1H, C6-Ha), 1.75 (dt, 2J = 14.0 Hz, 3J = 3.9 Hz, 1H, C6-
Hb); 13C NMR (75.5 MHz, CDCl3):  197.9 (C5), 166.6 (C13), 152.4 (CO2Me), 145.1 
(C14a), 138.1 (C8a), 136.4 (C12a), 132.5 (C10), 130.6 (C2), 129.5 (C12), 128.8 (C11), 
128.2 (C9), 126.2 (C3), 125.6 (C4), 120.6 (C1), 119.6 (C4a), 90.7 (C5a), 53.5 (CH3), 
44.9 (C6), 34.3 (C7); IR (KBr): max = 3423 (br s), 2925 (m), 1719 (s), 1655 (s), 1600 
(m), 1426 (m), 1313 (m), 1061 (w), 766 (m) cm-1; LRMS (ES+): m/z (%) 408.93 (100) 
[M+Na]+; HRMS (ES+): m/z calcd for C19H15N2O5NaCl [M+Na]+: 409.0567; found 
409.0560. 
8-Ethyl carboxylate-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-diazocin-
5,13-dione (2e): White powder  (21 mg, 93%), mp 191-192 oC; 1H NMR (300 MHz, 
CDCl3):  8.30 (d, 3J = 8.4 Hz, 1H, C1-H), 7.74-7.66 (m, 2H, C2-H, C4-H), 7.56-7.48 
(m, 2H, C12-H, C10-H), 7.41-7.34 (m, 1H, C11-H), 7.27-7.17 (m, 2H, C3-H, C9-H), 
4.18 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 4.14-4.04 (m, 1H, CH2(a)CH3), 3.98-
3.86 (m, 1H, CH2(b)CH3), 3.82 (br s, 1H, OH), 3.45 (ddd, 2J = 14.0 Hz, 3J = 12.0 Hz, 3J 
= 4.0 Hz, 1H, C7-Hb), 2.27 (ddd, 2J = 14.0 Hz, 3J = 12.0 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 
1.69 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.10 (t, 3J = 7.2 Hz, 3H, CH2CH3); 13C 
NMR (75.5 MHz, CDCl3):  199.3 (C5), 166.5 (C13), 155.0 (CO2Me), 151.9 (C14a), 
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138.3 (C8a), 138.2 (C2), 136.7 (C12a), 132.1 (C10), 129.4 (C12), 128.5 (C11), 128.1 
(C9), 125.3 (C3), 124.7 (C4), 121.4 (C4a), 120.2 (C1), 90.5 (C5a), 62.1 (OCH2CH3), 
44.9 (C7), 34.0 (C6), 14.7 (OCH2CH3); IR (KBr): max = 3286 (s), 2986 (m), 2956 (m), 
1733 (s), 1673 (s), 1601 (m), 1458 (m), 1017 (m), 756 (m) cm-1; LCMS (ES+): m/z (%) 
366.88 (100) [M+], 383.90 (80) [M+H2O]+; HRMS (ES+): m/z calcd for C20H18N2O5Na 
[M+Na]+: 389.1215; found 389.1204. 
8-(Ethyl carboxylate)-3-pentyloxy-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-
8,14-diazocin-5,13-dione (2f): Brown oil (22 mg, 0.05 mmol, 99%), 1H NMR (300 MHz, 
CDCl3): δ = 8.23 (d, 3J = 9.0 Hz, 1H, C1-H), 7.55-7.48 (m, 2H, C10-H, C12-H), 7.38 
(ddd, 3J = 7.5 Hz, 3J = 7.5 Hz, 4J = 1.0 Hz, 1H, C11-H), 7.28 (dd, 3J = 9.0 Hz, 4J = 3.0 
Hz, 1H, C2-H), 7.21-7.17 (m, 1H, C9-H), 7.05 (d, 4J = 3.0 Hz, 1H, C4-H), 4.23 (dt, 2J 
= 14.2 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 4.18-4.06 (m, 1H, OCH2(a)CH3), 4.00-3.88 (m, 1H, 
OCH2(b)CH3), 3.96 (t, 3J = 6.5 Hz, 2H, OCH2), 3.69 (br s, 1H, OH), 3.47 (ddd, 2J = 13.3 
Hz, 3J = 12.0 Hz, 3J = 3.0 Hz, 1H, C7-Hb), 2.31 (ddd, 2J = 13.3 Hz, 3J = 12.0 Hz, 3J = 
4.0 Hz, 1H, C6-Ha), 1.82 (qt, 3J = 6.5 Hz, 3J = 6.5 Hz, 2H, OCH2CH2), 1.72 (dt, 2J = 
14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.52-1.34 (m, 4H, CH2CH2CH3), 1.12 (t, 3J = 7.0 Hz, 
3H, OCH2CH3), 0.96 (t, 3J = 6.5 Hz, 3H, CH2CH2CH3); 13C NMR (75.5 MHz, CDCl3):  
199.5 (C5), 165.9 (C13), 156.6 (C3), 154.8 (CO2Me), 146.1 (C14a), 138.3 (C8a), 136.7 
(C12a), 132.0 (C10), 129.4 (C12), 128.4 (C11), 127.9 (C9), 127.5 (C2), 122.1 (C4a), 
121.5 (C1), 105.9 (C4), 90.8 (C5a), 68.7 (OCH2R), 61.9 (OCH2CH3), 44.9 (C7), 34.0 
(C6), 29.7 (OCH2CH2R), 28.7 (OCH2CH2CH2R), 22.4 (CH2CH3), 14.7 (CH2CH3) 14.2 
(OCH2CH3); IR (NaCl): max = 3422 (w), 2955 (m), 2928 (m), 2858 (m), 1719 (s) (C=O), 
1650 (s) (C=O), 1620 (m), 1459 (m), 1265 (m), 741 (w) cm-1; LCMS (ES+): (purity 99%) 
m/z (%) 452.91 (100) [M+H]+, 469.93 (70) [M+H2O]+; HRMS (ES+): m/z calcd for 
C25H28N2O6Na [M+Na]+: 475.1947; found 475.1948. 
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3-Methyl-8-(ethyl carboxylate)-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2g): White powder (21 mg, 90%), mp 196 oC (dec.); 1H NMR (300 
MHz, CDCl3):  8.19 (d, 3J = 8.5 Hz, 1H, C1-H), 7.55-7.49 (m, 3H, C4-H, C10-H, C12-
H), 7.45-7.43 (m, 1H, C2-H), 7.38 (ddd, 3J = 7.3 Hz, 3J = 7.3 Hz, 4J = 1.2 Hz, 1H, C11-
H), 7.19 (d, 3J = 7.3 Hz, 1H, C9-H), 4.20 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 
4.15-4.06 (m, 1H, OCH2(a)), 3.97-3.88 (m, 1H, OCH2(b)), 3.78 (br s, 1H, OH), 3.46 (ddd, 
2J = 12.8 Hz, 3J = 12.8 Hz, 3J = 3.4 Hz, 1H, C7-Hb), 2.39 (s, 3H, ArCH3), 2.28 (ddd, 2J 
= 12.8 Hz, 3J = 12.8 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 1.70 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 
1H, C6-Hb), 1.10 (t, 3J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (75.5 MHz, CDCl3):  199.5 
(C5), 166.3 (C13), 154.9 (CO2Me), 149.9 (C14a), 139.3 (C2), 138.4 (C8a), 136.8 
(C12a), 135.4 (C3), 132.0 (C10), 129.4 (C12), 128.5 (C11), 128.1 (C9), 124.2 (C4), 
121.4 (C4a), 120.0 (C1), 90.7 (C5a), 62.1 (OCH2CH3), 44.9 (C7), 34.0 (C6), 21.0 
(ArCH3), 14.7 (OCH2CH3); IR (KBr): max = 3286 (s), 1735 (s) (C=O), 1708 (s) (C=O), 
1648 (s) (C=O), 1489 (m), 1389 (m), 1266 (m) 764 (m) (Ar-H) cm-1; LCMS (ES+): (purity 
98%) m/z (%) 380.90 (100) [M+H]+, 397.82 (70) [M+H2O]+; HRMS (ES+): m/z calcd for 
C21H20N2O5Na [M+Na]+: 403.1371; found 403.1368. 
2-Chloro-8-(ethyl carboxylate)-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2h): White powder (22 mg, 99%), mp 148-149 oC; 1H NMR (300 
MHz, CDCl3):  8.41 (d, 4J = 1.5 Hz, 1H, C1-H), 7.66 (d, 3J = 8.2 Hz, 1H, C4-H), 7.58-
7.52 (m, 2H, C10-H, C12-H), 7.43 (ddd, 3J = 7.8 Hz, 3J = 7.8 Hz, 4J = 1.3 Hz, 1H, C11-
H), 7.25 (dd, 3J = 8.2 Hz, 4J = 1.5 Hz, 1H, C3-H), 7.21 (d, 3J = 7.8 Hz, 1H, C9-H), 4.21 
(dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 4.16-4.07 (m, 1H, OCH2(a)CH3), 4.02-3.93 
(m, 1H, OCH2(b)CH3), 3.53 (br s, 1H, OH), 3.47 (ddd, 2J = 13.0 Hz, 3J = 12.0 Hz, 3J = 
4.0 Hz, 1H, C7-Hb), 2.33 (ddd, 2J = 13.0 Hz, 3J = 11.8 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 
1.73 (dt, 2J = 14.0 Hz, 3J = 3.9 Hz, 1H, C6-Hb), 1.12 (t, 3J = 7.0 Hz, 3H, OCH2CH3); 
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13C NMR (75.5 MHz, CDCl3):  198.2 (C5), 166.6 (C13), 155.0 (CO2Me), 152.4 (C14a), 
144.9 (C2), 138.3 (C8a), 136.4 (C12a), 132.5 (C10), 129.4 (C12), 128.3 (C11), 128.2 
(C9), 126.1 (C3), 126.0 (C4), 120.5 (C1), 119.7 (C4a), 90.9 (C5a), 62.2 (OCH2CH3), 
44.8 (C6), 34.1 (C7), 14.7 (OCH2CH3); IR (KBr): max = 3420 (br s), 2927 (m), 1725 (s) 
(C=O), 1665 (s) (C=O), 1602 (m), 1458 (m), 1376 (m), 1260 (w), 767 (m) cm-1; LCMS 
(ES+): (purity 99%) m/z (%) 400.86 (100) [M+H]+, 417.87 (80) [M+H2O]+; HRMS (ES+): 
m/z calcd for C20H17N2O5NaCl [M+Na]+: 423.0825; found 423.0818. 
8-N-Butyl carboxamide-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-diazocin-
5,13-dione (2i) 15,16: White powder (18 mg, 74%), mp 235-236 oC; 1H NMR (300 MHz, 
CDCl3):  8.31 (d, 3J = 8.5 Hz, 1H, C1-H), 7.70-7.62 (m, 2H, C2-H, C4-H), 7.52 (ddd, 
3J = 7.6 Hz, 3J = 7.6 Hz, 4J = 1.7 Hz, C10-H), 7.44-7.40 (m, 1H, C12-H), 7.37-7.32 (m, 
1H, C11-H), 7.24-7.18 (m, 2H, C3-H, C9-H), 4.82 (br s, 1H, OH), 4.19 (dt, 2J = 14.0 
Hz, 3J = 4.0 Hz, 1H, C7-Ha), 4.06 (t, 3J = 6.0 Hz, 1H, NH), 3.26 (ddd, 2J = 12.0 Hz, 3J 
= 11.5 Hz, 3J = 3.0 Hz, 1H, C7-Hb), 3.06-2.96 (m, 1H, NHCH(a)), 2.88-2.79 (m, 1H, 
NHCH(b)), 2.07 (ddd, 2J = 12.0 Hz, 3J = 10.2 Hz, 3J = 3.0 Hz, 1H, C6-Ha), 1.59 (dt, 2J 
= 14.0 Hz, 3J = 3.0 Hz, 1H, C6-Hb), 1.29-1.20 (m, 2H, NHCH2CH2), 1.19-1.10 (m, 2H, 
NHCH2CH2CH2), 0.82 (t, 3J = 7.5 Hz, 3H, CH3); 13C NMR (75.5 MHz, CDCl3):  199.4 
(C5), 166.3 (C13), 156.2 (NCONH), 151.5 (C14a), 138.4 (C8a), 138.0 (C2), 137.6 
(C12a), 132.7 (C10), 130.0 (C12), 129.3 (C11 & C9), 125.4 (C3), 124.5 (C4), 121.6 
(C4a), 120.3 (C1), 90.7 (C5a), 43.8 (C7), 40.6 (NHCH2), 35.0 (C6), 32.4 (NHCH2CH2), 
20.0 (NHCH2CH2CH2), 13.9 (CH3); IR (KBr): max = 3389 (s), 3246 (s), 2956 (m), 2872 
(m), 1736 (s) (C=O), 1635 (s) (C=O), 1625 (m), 1535 (m), 1463 (m), 1381 (m), 764 
(m) cm-1; LRMS (ES+): m/z (%) 416.08 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C22H23N3O4Na [M+Na]+: 416.1586; found 416.1585. 
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8-(N-Butyl carboxamide)-3-pentyloxy-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-
8,14-diazocin-5,13-dione (2j): Yellow oil (8 mg, 36%), 1H NMR (300 MHz, CDCl3):  
8.33 (d, 3J = 9.0 Hz, 1H, C1-H), 7.61-7.55 (m, 2H, C10-H, C12-H), 7.50-7.44 (m, 1H, 
C11-H), 7.31 (dd, 3J = 9.0 Hz, 4J = 2.9 Hz, 1H, C2-H), 7.29-7.25 (m, 1H, C9-H), 7.12 
(d, 4J = 2.9 Hz, 1H, C4-H), 4.44 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-Ha), 4.11 (t, 3J 
= 5.8 Hz, 1H, NH), 3.98 (t, 3J = 6.7 Hz, 2H, OCH2), 3.36 (ddd, 2J = 13.3 Hz, 3J = 11.7 
Hz, 3J = 2.9 Hz, 1H, C7-Hb), 3.22-3.10 (m, 1H, NHCH2(a)), 3.04-2.92 (m, 1H, NHCH2(b)), 
2.30 (ddd, 2J = 13.3 Hz, 3J = 11.7 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 1.87-1.77 (m, 2H, 
OCH2CH2), 1.72 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.50-1.30 (m, 4H, 
OC2H4CH2CH2CH3), 1.29-1.15 (m, 4H, NHCH2CH2CH2CH3), 0.96 (t, 3J = 7.0 Hz, 3H, 
OC4H8CH3), 0.87 (t, 3J = 7.2 Hz, 3H, NHC3H6CH3); 13C NMR (75.5 MHz, CDCl3):  
199.4 (C5), 166.7 (C13), 156.8 (C3), 156.1 (NCONH), 146.1 (C14a), 138.5 (C8a), 
137.8 (C12a), 132.7 (C10), 130.1 (C12), 129.4 (C11 & C9), 127.4 (C2), 122.4 (C4a), 
121.6 (C1), 106.0 (C4), 90.9 (C5a), 68.8 (OCH2), 44.0 (C7), 40.7 (NCONHCH2), 35.3 
(C6), 32.6 (NCONHCH2CH2) 28.9 (OCH2CH2CH2CH2CH3), 28.3 
(OCH2CH2CH2CH2CH3), 22.6 (OCH2CH2CH2CH2CH3), 20.0 (NCONHCH2CH2CH2), 
14.2 (OCH2CH2CH2CH2CH3), 14.0 (NCONHCH2CH2CH2CH3); IR (NaCl): max = 2957 
(m), 2872 (m) 1728 (s) (C=O), 1637 (s), 1524 (m), 1488 (m), 1279 (m) cm-1; LRMS 
(ES+): m/z (%) 502.13 (100) [M+Na]+; HRMS (ES+): m/z calcd for C27H33N3O5Na 
[M+Na]+: 502.2318; found 502.2314. 
3-Methyl-8-N-butyl carboxamide-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2k): White powder (7 mg, 29%), mp 204-205 oC; 1H NMR (300 
MHz, CDCl3):  8.26 (d, 3J = 8.5 Hz, 1H, C1-H), 7.60-7.41 (m, 5H, C4-H, C10-H, C12-
H, C2-H, C11-H), 7.27-7.23 (m, 1H, C9-H), 4.36 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C7-
Ha), 4.08 (t, 3J = 5.9 Hz, 1H, NH), 3.66 (br s, 1H, OH), 3.33 (ddd, 2J = 13.0 Hz, 3J = 
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11.8 Hz, 3J = 4.0 Hz, 1H, C7-Hb), 3.18-3.06 (m, 1H, NHCH(a)), 3.00-2.88 (m, 1H, 
NHCH(b)), 2.40 (s, 3H, ArCH3), 2.24 (ddd, 2J = 13.0 Hz, 3J = 11.8 Hz, 3J = 4.0 Hz, 1H, 
C6-Ha), 1.67 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.37-1.14 (m, 4H, 
NHCH2CH2CH2), 0.86 (t, 3J = 7.3 Hz, 3H, CH2CH3); 13C NMR (75.5 MHz, CDCl3):  
199.4 (C5), 166.1 (C13), 156.4 (NCON), 149.7 (C14a), 139.3 (C2), 138.4 (C8a), 137.7 
(C12a), 135.5 (C3), 132.6 (C10), 130.0 (C12), 129.3 (C11 & C9), 124.2 (C4), 121.5 
(C4a), 120.0 (C1), 90.7 (C5a), 43.8 (C7), 40.6 (NHCH2), 35.1 (C6), 32.5 (NHCH2CH2), 
21.0 (ArCH3), 20.0 (NHCH2CH2CH2), 13.9 (NHCH2CH2CH2CH3); IR (KBr): max = 3236 
(s), 1722 (s) (C=O), 1638 (s) (C=O), 1525 (m), 1490 (w), 1152 (w), 742 (m) cm-1; LRMS 
(ES+): m/z (%) 430.04 (100) [M+Na]+; HRMS (ES+): m/z calcd for C23H25N3O4Na 
[M+Na]+: 430.1743; found 430.1757. 
2-Chloro-8-N-butyl carboxamide-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-8,14-
diazocin-5,13-dione (2l): White powder (10 mg, 44%), mp 211-212 oC; 1H NMR (300 
MHz, CDCl3):  8.44 (d, 4J = 1.8 Hz, 1H, C1-H), 7.66 (d, 3J = 8.0 Hz, 1H, C4-H), 7.63-
7.45 (m, 3H, C10-H, C12-H, C11-H), 7.29-7.23 (m, 2H, C3-H, C9-H), 4.33 (dt, 2J = 
14.0 Hz, 3J = 3.8 Hz, 1H, C7-Ha), 4.07 (t, 3J = 5.6 Hz, 1H, NH), 3.86 (br s, 1H, OH), 
3.34 (ddd, 2J = 12.8 Hz, 3J = 11.6 Hz, 3J = 3.8 Hz, 1H, C7-Hb), 3.19-3.07 (m, 1H, 
NHCH2(a)), 2.98-2.86 (m, 1H, NHCH2(b)), 2.25 (ddd, 2J = 13.0 Hz, 3J = 10.7 Hz, 3J = 
4.0 Hz, 1H, C6-Ha), 1.68 (dt, 2J = 14.0 Hz, 3J = 3.9 Hz, 1H, C6-Hb), 1.37-1.14 (m, 4H, 
NHCH2CH2CH2), 0.89 (t, 3J = 7.0 Hz, 3H, CH2CH3); 13C NMR (75.5 MHz, CDCl3):  
192.5 (C5), 161.5 (C13), 156.2 (NCON), 152.4 (C14a), 144.9 (C2), 138.1 (C8a), 136.2 
(C12a), 132.9 (C10), 130.0 (C12), 129.3 (C9), 129.0 (C11), 125.3 (C4), 121.1(C4a), 
120.5 (C1), 90.9 (C5a), 43.7 (C7), 40.6 (NHCH2), 35.0 (C6), 32.6 (NHCH2CH2), 19.9 
(NHCH2CH2CH2), 13.9 (NHCH2CH2CH2CH3); IR (KBr): max = 3416 (m), 1741 (s) 
(C=O), 1655 (s) (C=O), 1599 (m), 1458 (w), 1367 (w), 1019 (m) cm-1; LRMS (ES+): 
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m/z (%) 449.99 (100) [M+Na]+; HRMS (ES+): m/z calcd for C22H22N3O4NaCl [M+Na]+: 
450.1197; found 450.1178. 
8-(Cyclopropanemethyl)carboxamide-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-
8,14-diazocin-5,13-dione (2m): White powder (9 mg, 0.02 mmol, 36%), mp 236-237 
oC; 1H NMR (300 MHz, CDCl3):  8.43 (d, 3J = 8.3 Hz, 1H, C1-H), 7.80-7.71 (m, 2H, 
C2-H, C4-H), 7.64-7.58 (m, 2H, C10-H, C12-H), 7.54-7.48 (m, 1H, C11-H), 7.32-7.26 
(m, 2H, C3-H, C9-H), 4.51-4.42 (m, 1H, C7-Ha), 4.21-4.17 (m, 1H, NH), 3.44-3.33 (m, 
1H, C7-Hb), 3.01-2.92 (m, 2H, NHCH2), 2.40-2.30 (m, 1H, C6-Ha), 1.78-1.70 (m, 1H, 
C6-Hb), 0.89-0.79 (m, 1H, NHCH2CH), 0.42-0.36 (m, 2H, cyclopropane CH2), 0.10-
0.04 (m, 2H, cyclopropane CH2); 13C NMR (300 MHz, d6-DMSO): 199.1 (C5), 166.1 
(C13), 155.7 (NCONH), 151.5 (C14a), 138.5 (C8a), 137.8 (C12a), 137.5 (C2), 132.1 
(C10), 129.4 (C11 & C9), 128.1 (C12), 124.7 (C3), 124.0 (C4), 121.3 (C4a), 119.5 
(C1), 90.3 (C5a), 43.9 (C7), 43.6 (NHCH2), 33.9 (C6), 11.5 (NCH2CH), 3.0 
(cyclopropane CH2), 2.8 (cyclopropane CH2); IR (KBr): max = 3366 (s), 3240 (s), 1736 
(s) (C=O), 1649 (s) (C=O), 1630 (s), 1601 (m), 1536 (m), 1464 (m), 764 (w) cm-1; 
LRMS (ES+): m/z (%) 414.02 (100) [M+Na]+; HRMS (ES+): m/z calcd for C22H21N3O4Na 
[M+Na]+: 414.1430; found 414.1412. 
8-(2-Methoxyethyl carboxamide)-3-pentyloxy-6,7-dihydro-5a-hydroxy-indolin[1,2-a] 
benzo[c]-8,14-diazocin-5,13-dione (2n): White crystals (8 mg, 33%), mp 139-140 oC; 
1H NMR (300 MHz, CDCl3):  8.31 (d, 3J = 9.0 Hz, 1H, C1-H), 7.59-7.53 (m, 2H, C10-
H, C12-H), 7.47-7.41 (m, 1H, C11-H), 7.29 (dd, 3J = 9.0 Hz, 4J = 2.9 Hz, 1H, C2-H), 
7.27-7.23 (m, 1H, C9-H), 7.08 (d, 4J = 2.9 Hz, 1H, C4-H), 4.45-4.33 (m, 2H, C7-Ha, 
NH), 3.98 (t, 3J = 6.6 Hz, 2H, OCH2), 3.41-3.19 (m, 8H, C7-Hb, NHC2H4OCH3), 2.26 
(ddd, 2J = 13.0 Hz, 3J = 10.5 Hz, 3J = 4.0 Hz, 1H, C6-Ha), 1.82 (quintet, 3J = 7.3 Hz, 
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2H, OCH2CH2), 1.70 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb), 1.53-1.34 (m, 4H, 
OCH2CH2CH2CH2CH3), 0.96 (t, 3J = 6.9 Hz, 3H, OCH2CH2CH2CH2CH3); 13C NMR 
(75.5 MHz, CDCl3):  198.9 (C5), 166.7 (NCONHR), 164.5 (C13), 156.4 (C3), 145.7 
(C14a), 138.3 (C8a), 137.6 (C12a), 132.6 (C10), 130.1 (C12), 129.3 (C11), 129.2 (C9), 
127.4 (C2), 122.3 (C4a), 121.6 (C1), 106.0 (C4), 90.8 (C5a), 71.8 
(NCONHCH2CH2OCH3), 68.9 (OCH2), 58.9 (OCH3), 44.0 (C7), 40.5 
(NCONHCH2CH2OCH3), 35.2 (C6), 29.0 (OCH2CH2CH2CH2CH3), 28.3 
(OCH2CH2CH2CH2CH3), 22.7 (OCH2CH2CH2CH2CH3), 14.2 (CH2CH3); IR (KBr): max 
=  3362 (s), 2936 (m), 1734 (s) (C=O), 1638 (s) (C=O), 1523 (w), 1489 (m), 1090 (w), 
733 (m) cm-1; LCMS (ES+): (purity 99%) m/z (%) 481.86 (100) [M+Na]+; HRMS (ES+): 
m/z calcd for C25H30N3O6 [M+H]+: 468.2135; found 468.2137. 
8-(2-Morpholinoethyl)carboxamide-6,7-dihydro-5a-hydroxy-indolin[1,2-a]benzo[c]-
8,14-diazocin-5,13-dione (2o): White powder (20 mg, 67%), mp 155-156 oC; 1H NMR 
(300 MHz, CDCl3):  8.34 (d, 3J = 8.7 Hz, 1H, C1-H), 7.72-7.66 (m, 2H, C2-H, C4-H), 
7.55 (ddd, 3J = 7.9 Hz, 3J = 7.9 Hz, 4J = 1.7 Hz, 1H, C10-H), 7.49 (dd, 3J = 7.9 Hz, 4J 
= 1.7 Hz, 1H, C12-H), 7.41 (ddd, 3J = 7.9 Hz, 3J = 7.9 Hz, 4J = 1.7 Hz, 1H, C11-H), 
7.26-7.19 (m, 2H, C3-H, C9-H), 4.80 (t, 3J = 4.9 Hz, 1H, NH), 4.23 (dt, 2J = 14.0 Hz, 
3J = 3.9 Hz, 1H, C7-Ha), 3.49-3.40 (m, 4H, morpholine 2x CH2O), 3.33 (ddd, 2J = 13.0 
Hz, 3J = 11.8 Hz, 3J = 3.9 Hz, 1H, C7-Hb), 3.13-2.97 (m, 2H, CONHCH2), 2.35-2.22 
(m, 6H, CONHCH2CH2N(CH2CH2)2O), 2.14 (ddd, 2J = 14.0 Hz, 3J = 11.8 Hz, 3J = 4.0 
Hz, 1H, C6-Ha), 1.66 (dt, 2J = 14.0 Hz, 3J = 4.0 Hz, 1H, C6-Hb); 13C NMR (75.5 MHz, 
CDCl3):  199.6 (C5), 166.2 (C13), 156.2 (NCONH), 151.6 (C14a), 138.5 (C8a), 137.9 
(C2), 137.8 (C12a), 132.4 (C10), 130.0 (C12), 129.2 (C11), 129.0 (C9), 125.2 (C3), 
124.4 (C4), 121.7 (C4a), 120.3 (C1), 90.8 (C5a), 67.0 (CONHCH2CH2N(CH2CH2)2O), 
56.8 (CONHCH2CH2), 52.9 (CONHCH2CH2N(CH2CH2)2O), 43.6 (C7), 36.7 
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(CONHCH2CH2), 35.1 (C6); IR (KBr): max = 1735 (s) (C=O), 1647 (s) (C=O), 1620 
(m), 1524 (m), 1459 (m), 1300 (m), 1115 (m), 762 (m) cm-1; LRMS (ES+): m/z (%) 
473.03 (100) [M+Na]+, 451.06 (75) [M+H]+; HRMS (ES+): m/z calcd for C24H26N4O5Na 
[M+Na]+: 473.1801; found 473.1779. 
Typical Procedure for the Synthesis of 3. 
Alkoxide nucleophiles: Reactions were conducted in parallel using the Radleys 
Greenhouse Parallel synthesiser. To a solution of the N-acyl cyclic urea 1 (0.06 mmol, 
1.0 eq.) in anhydrous methanol or ethanol (2 mL) was added the sodium alkoxide 
(sodium methoxide or sodium ethoxide were added as powders (0.12 mmol, 2.0 eq.). 
The reaction mixture was stirred at room temperature for 16 h. The reaction mixtures 
were evaporated in parallel, re-dissolved in dichloromethane (2 x 4.0 mL) and washed 
with NaHCO3(aq.) (2 x 2.0 mL). The mixtures were passed through an IsoluteTM phase 
separator and the organic layer was then dried (Na2SO4 cartridge) and concentrated 
in vacuo to give a solid which was purified by recrystallisation from acetonitrile to afford 
the title compound. 
Amine nucleophiles: N-acyl cyclic urea 1 (0.06 mmol, 1.0 eq.) in a glass microwave 
tube was added an excess of the relevant amine (n-butylamine, benzylamine, or 4-(2-
aminoethyl)morpholine) (0.6 mmol, 10 eq.) forming a slurry. The reaction mixture was 
irradiated to 80 oC, (maximum 150 W), with air flowing through the reaction chamber, 
for 5 minutes. Upon cooling to room temperature the reaction mixture was added 
KHSO4(aq.) (4.0 mL) and the organic material was extracted with dichloromethane (2 x 
4.0 mL) using an IsoluteTM phase separator. The organic layer was dried (Na2SO4 
cartridge) and concentrated in vacuo to give a solid which was purified by 
recrystallisation from acetonitrile to afford the title compound. 
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Methyl 1-(2-(methoxycarbonyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline-4-
carboxylate (3a) 15,16: Yellow powder (17 mg, 77%), mp 149-150 oC; 1H NMR (300 
MHz, CDCl3):  8.18 (dd, 3J = 8.5 Hz, 4J = 1.0 Hz, 1H, C5-H), 7.88 (dd, 3J = 8.0 Hz, 4J 
= 1.5 Hz, 1H, C3’-H), 7.63-7.52 (m, 2H, C8-H, C5’-H), 7.49-7.42 (m, 1H, C7-H), 7.36-
7.31 (m, 1H, C6’-H), 7.30-7.23 (m, 2H, C4’-H, C6-H), 4.20 (t, 3J = 8.0 Hz, 2H, C2-H2), 
4.04 (s, 3H, PyCO2CH3), 3.55-3.47 (m, 5H, C3-H2, ArCO2CH3); 13C NMR (75.5 MHz, 
CDCl3):  168.0 (ArCO2CH3), 166.8 (PyCO2CH3), 158.3 (C9a), 147.6 (C8a), 139.2 
(C1’), 132.3 (C5’), 131.2 (C4), 130.7 (C3’), 128.9 (C7), 128.6 (C3a), 127.0 (C2’), 126.9 
(C8), 124.9 (C5), 124.8 (C4’), 123.4 (C6), 122.9 (C6’), 120.9 (C4a), 52.3 (PyCO2CH3), 
51.9 (ArCO2CH3), 50.3 (C2), 26.9 (C3); IR (KBr): max = 2945 (m), 1725 (s) (C=O), 
1717 (s) (C=O), 1617 (m), 1597 (m), 1483 (m), 1228 (w), 754 (w) cm-1; LRMS (ES+): 
m/z (%) 363.38 (100) [M+H]+, 384.94 (65) [M+Na]+; HRMS (ES+): m/z calcd for 
C21H19N2O4 [M+H]+: 363.1345; found 363.1340. 
Methyl 1-(4’-methoxy-2-(methoxycarbonyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-
b]quinoline-4-carboxylate (3b): Yellow powder (11 mg, 48%), mp 156-157 oC; 1H NMR 
(300 MHz, CDCl3):  8.09 (dd, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H, C5-H), 7.50 (dd, 3J = 8.2 
Hz, 4J = 1.2 Hz, 1H, C8-H), 7.39-7.33 (m, 2H, C3’-H, C7-H), 7.23 (d, 3J = 8.8 Hz, 1H, 
C6’-H), 7.16 (ddd, 3J = 8.2 Hz, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H, C6-H), 7.04 (dd, 3J = 8.8 
Hz, 4J = 3.0 Hz, 1H, C5’-H), 4.07 (t, 3J = 7.6 Hz, 2H, C2-H2), 3.96 (s, 3H, PyCO2CH3), 
3.80 (s, 3H, ArOCH3), 3.45-3.39 (m, 5H, C3-H2, ArCO2CH3); 13C NMR (75.5 MHz, 
CDCl3):  168.3 (ArCO2Me), 167.5 (PyCO2Me), 159.4 (C4’), 157.1 (C9a), 148.1 (C8a), 
132.7 (C1’), 131.1 (C4), 128.9 (C7), 128.8 (C2’), 128.6 (C3a), 127.0 (C8), 126.3 (C5’), 
125.0 (C5), 123.1 (C6), 120.8 (C4a), 118.9 (C3’), 115.4 (C6’), 55.9 (ArOCH3), 52.3 
(PyCO2CH3), 52.1 (ArCO2CH3), 51.1 (C2), 27.0 (C3); IR (KBr): 3422 (s), 2925 (m), 
1719 (s), 1618 (s), 1500 (m), 1438 (m), 1220 (m), 768 (w) cm-1; LRMS (ES+): m/z (%) 
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415.07 (100) [M+Na]+, 393.09 (60) [M+H]+; HRMS (ES+): m/z calcd for C22H21N2O5 
[M+H]+: 393.1450; found 393.1465. 
6-Chloro methyl-1-(2-(methoxycarbonyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b] 
quinoline-4-carboxylate (3c): Yellow powder (16 mg, 74%), mp 164-165 oC; 1H NMR 
(300 MHz, CDCl3):  8.26 (d, 4J = 2.4 Hz, 1H, C5-H), 7.88 (dd, 3J = 7.7 Hz, 4J = 1.6 
Hz, 1H, C3’-H), 7.60-7.51 (m, 2H, C8-H, C5’-H), 7.39 (dd, 3J = 8.9 Hz, 4J = 2.5 Hz, 1H, 
C7-H), 7.35-7.27 (m, 2H, C4’-H, C6’-H), 4.21 (t, 3J = 7.7 Hz, 2H, C2-H2), 4.05 (s, 3H, 
PyCO2CH3), 3.56-3.51 (m, 5H, C3-H2, ArCO2CH3); 13C NMR (75.5 MHz, d6-DMSO):  
167.1 (ArCO2CH3), 165.6 (PyCO2CH3), 158.5 (C9a), 145.7 (C8a), 138.6 (C1’), 132.6 
(C5’), 130.9 (C4), 130.1 (C3’), 129.4 (C3a), 129.2 (C7), 127.8 (C8), 127.3 (C2’), 126.7 
(C6), 125.1 (C5), 123.9 (C4’), 123.6 (C6’), 121.1 (C4a), 52.8 (PyCO2CH3), 51.6 
(ArCO2CH3), 49.9 (C2), 26.5 (C3); IR (KBr): max = 2926 (m), 1715 (s) (C=O), 1602 
(m), 1485 (m) 1265 (s), 743 (m) cm-1; LCMS (ES+): m/z (%) 396.75 (100) [M]+, 398.79 
(70) [M+H]+; HRMS (ES+): m/z calcd for C21H17N2O4Cl [M+H]+: 397.0752; found 
397.0724; An analytical sample of 171(1,2,5,1) was prepared by recrystallisation from 
DCM; Anal. calc’d for C21H17ClN2O4: C, 63.56; H, 4.32; N, 7.06; found: C, 63.64; H, 
4.33; N, 7.23. 
6-Chloro ethyl-1-(2-(ethoxycarbonyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline-
4-carboxylate (3d): Yellow solid (25 mg, 7%), mp 165-166 oC; 1H NMR (300 MHz, 
CDCl3):  8.27 (d, 4J = 2.3 Hz, 1H, C5-H), 7.91 (dd, 3J = 7.7 Hz, 4J = 1.6 Hz, 1H, C3’-
H), 7.56 (ddd, 3J = 7.7 Hz, 3J = 7.7 Hz, 4J = 1.6 Hz, 1H, C5’-H), 7.51 (d, 3J = 8.9 Hz, 
1H, C8-H), 7.38 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, C7-H), 7.33 (dd, 3J = 7.7 Hz, 4J = 
1.6 Hz, 1H, C4’-H), 7.28 (dd, 3J = 7.7 Hz, 4J = 1.6 Hz, 1H, C6’-H), 4.51 (q, 3J = 7.2 Hz, 
2H, PyCO2CH2CH3), 4.20 (t, 3J = 7.6 Hz, 2H, C2-H2), 3.93 (q, 3J = 7.2 Hz, 2H, 
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ArCO2CH2CH3), 3.53 (t, 3J = 7.6 Hz, 2H, C3-H2), 1.48 (t, 3J = 7.2 Hz, 3H, 
PyCO2CH2CH3), 1.03 (t, 3J = 7.2 Hz, 3H, ArCO2CH2CH3); 13C NMR (300 MHz, CDCl3): 
 167.4 (ArCO2R), 165.9 (PyCO2R), 159.1 (C9a), 146.5 (C8a), 139.2 (C1’), 132.6 
(C5’), 131.1 (C3’), 130.4 (C4), 130.0 (C6), 129.4 (C7), 128.9 (C3a), 128.2 (C8), 127.7 
(C2’), 125.5 (C6’), 124.4 (C5), 123.9 (C4’), 121.8 (C4a), 61.8 (PyCO2CH2CH3), 61.0 
(ArCO2CH2CH3), 50.7 (C2), 27.2 (C3), 14.5 (PyCO2CH2CH3), 14.0 (ArCO2CH2CH3); 
IR (KBr): max = 2986 (m) (CH2), 1725 (s) (C=O), 1675 (m) (C=O), 1219 (m), 746 (m) 
(Ar-H) cm-1; LRMS (ES+): m/z (%) 424.90 (100) [M+H]+, 446.88 (30) [M+Na]+; HRMS 
(ES+): m/z calcd for C23H22N2O4Cl [M+H]+: 425.1268; found 425.1240. 
N-butyl 1-(2-(butylcarbamoyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline-4-
carboxamide (3e): White powder (16 mg, 61%), mp 130-131 oC; 1H NMR (300 MHz, 
CDCl3):  7.73 (dd, 3J = 8.2 Hz, 4J = 1.1 Hz, 1H, C5-H), 7.67 (dd, 3J = 8.1 Hz, 4J = 1.8 
Hz, 1H, C3’-H), 7.58-7.53 (m, 1H, C6’-H), 7.52-7.48 (m, 1H, C5’-H), 7.47-7.41 (m, 1H, 
C7-H), 7.39-7.33 (m, 2H, C8-H, C6-H), 7.27-7.22 (m, 1H, C4’-H), 7.04 (t, 3J = 5.2 Hz, 
1H, NHb), 6.01 (t, 3J = 5.5 Hz, 1H, NHa), 4.09 (t, 3J = 7.7 Hz, 2H, C2-H2), 3.57 (q, 3J = 
5.5 Hz, 2H, C(a1)-H2), 3.32 (t, 3J = 7.7 Hz, 2H, C3-H2), 3.13 (q, 3J = 5.2 Hz, 2H, C(b1)-
H2), 1.73-1.62 (m, 2H, C(a2)-H2), 1.54-1.41 (m, 2H, C(a3)-H2), 1.22-1.07 (m, 4H, 
C(b2)-H2, C(b3)-H2), 1.01 (t, 3J = 7.3 Hz, 3H, C(a4)-H3), 0.69 (t, 3J = 7.1 Hz, 3H, C(b4)-
H3); 13C NMR (75.5 MHz, CDCl3):  168.3 (CONHb), 166.8 (CONHa), 160.3 (C9a), 
147.4 (C8a), 138.3 (C4), 137.7 (C1’), 131.4 (C5’), 129.6 (C7), 129.3 (C3’), 127.3 (C6’), 
126.7 (C6), 126.6 (C8), 124.6 (C5), 123.8 (C3a), 123.4 (C4’), 120.8 (C2’), 118.2 (C4a), 
52.5 (C2), 39.7 (2 x height: C(a1), C(b1)), 31.9 (C(a2)), 31.3 (C(b2)), 25.2 (C3), 20.3 
(C(b3)), 20.1 (C(a3)), 13.9 (C(a4)), 13.7 (C(b4)); IR (KBr): max = 1647 (br s) (C=O), 
1485 (m) 1265 (s), 741 (s) cm-1; LRMS (ES+): m/z (%) 467.09 (100) [M+Na]+, 445.14 
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(25) [M+H]+, 911.20 (25) [2M+Na]+; HRMS (ES+): m/z calcd for C27H32N4O2Na 
[M+Na]+: 467.2423; found 467.2426. 
N-benzyl 1-(2-(benzylcarbamoyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline-4-
carboxamide (3f): White powder (19 mg, 61%), mp 190 (dec.) oC; 1H NMR (300 MHz, 
d6-DMSO):  9.24 (t, 3J = 6.0 Hz, 3J = 6.0 Hz, 1H, NHa), 8.81 (t, 3J = 6.0 Hz, 3J = 6.0 
Hz, 1H, NHb), 7.63 (d, 3J = 8.1 Hz, 1H, C5-H), 7.60 (d, 3J = 7.5 Hz, 1H, C3’-H), 7.56-
7.51 (m, 2H, C5’-H, C8-H), 7.46-7.43 (m, 2H, C7-H, C4’-H), 7.42 (m, 4H, benzyl C-H), 
7.38-7.33 (m, 1H, C6’-H), 7.33 (m, 1H, Cp-H), 7.24-7.19 (m, 1H, C6-H), 7.14-7.10 (m, 
5H, benzyl C-H), 4.57 (d, 3J = 6.0 Hz, 2H, benzyl CH2a), 4.21 (d, 3J = 6.0 Hz, 2H, 
benzyl CH2b), 4.03 (t, 3J = 7.7 Hz, 2H, C2-H2), 3.14 (t, 3J = 7.7 Hz, 2H, C3-H2); 13C 
NMR (75.5 MHz, d6-DMSO):  167.8 (ArCONH), 165.8 (PyCONH), 159.2 (C9a), 147.2 
(C8a), 139.3 (Ci x 2), 138.6 (C1’), 137.3 (C4), 133.8 (C2’), 130.5 (C5’), 128.9 (C3’), 
128.5 (C7 & benzyl CH), 128.4 (benzyl CH x 2), 128.1 (benzyl CH x 2), 127.4 (benzyl 
CH x 2), 127.0 (benzyl CH x 2), 126.5 (Cp), 126.1 (C4’), 125.5 (C5 & C8), 124.5 (C6’), 
123.5 (C3a), 122.3 (C6), 120.9 (C4a), 50.8 (C2), 42.5 (benzyl CH2), 42.4 (benzyl CH2), 
24.5 (C3); IR (KBr): max = 2928 (m), 1648 (s) (C=O), 1598 (m), 1526 (m), 1480 (m), 
1450 (m), 1327 (w), 759 (w) cm-1; LRMS (ES+): m/z (%) 513.04 (100) [M+H]+, 535.01 
(15) [M+Na]+; HRMS (ES+): m/z calcd for C33H29N4O2 [M+H]+: 513.2291; found 
513.2293. 
N-butyl 1-(4’-methoxy-2-(butylcarbamoyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-
b]quinoline-4-carboxamide (3g): Yellow powder (10 mg, 40%), mp 111-112 oC; 1H 
NMR (300 MHz, d6-DMSO):  7.73 (dd, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H, C5-H), 7.57 (dd, 
3J = 8.2 Hz, 4J = 1.2 Hz, 1H, C8-H), 7.45 (ddd, 3J = 8.2 Hz, 3J = 8.2 Hz, 4J = 1.2 Hz, 
1H, C7-H), 7.36 (t, 3J = 5.9 Hz, 1H, NHb), 7.26-7.21 (m, 3H, C3’-H, C6’-H, C6-H), 7.03 
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(dd, 3J = 8.7 Hz, 4J = 3.0 Hz, 1H, C5’-H), 5.97 (t, 3J = 5.8 Hz, 1H, NHa), 4.02 (t, 3J = 
7.9 Hz, 2H, C2-H2), 3.86 (s, 3H, ArOCH3), 3.58 (q, 3J = 6.0 Hz, 2H, C(a1)-H2), 3.31 (t, 
3J = 7.9 Hz, 2H, C3-H2), 3.14 (q, 3J = 5.7 Hz, 2H, C(b1)-H2), 1.73-1.62 (m, 2H, C(a2)-
H2R), 1.54-1.41 (m, 2H, C(a3)-H2), 1.14-1.05 (m, 4H, C(b2)-H2, C(b3)-H2), 1.01 (t, 3J 
= 7.2 Hz, 3H, C(a4)-H3), 0.65 (t, 3J = 7.2 Hz, 3H, C(b4)-H3); 13C NMR (75.5 MHz, d6-
DMSO):  167.0 (CONHb), 165.6 (CONHa), 159.8 (C4’), 157.0 (C9a), 147.3 (C8a), 
136.3 (C1’), 132.1 (C2’), 131.4 (C4), 128.3 (C7), 128.0 (C8), 125.9 (C5’), 124.5 (C5), 
123.1 (C3a), 122.0 (C6), 120.8 (C4a), 115.9 (C3’), 113.8 (C6’), 55.5 (ArOCH3), 51.5 
(C2), 38.7 (C(a1)), 38.4 (C(b1)), 31.2 (C(a2)), 30.9 (C(b2)), 24.4 (C3), 19.7 (C(b3)), 
19.6 (C(a3)), 13.7 (C(a4)), 13.6 (C(b4)); IR (KBr): 3422 (s), 2925 (m), 1719 (s), 1618 
(s), 1500 (m), 1438 (m), 1220 (m), 768 (w) cm-1; LRMS (ES+): m/z (%) 497.11 (100) 
[M+Na]+; HRMS (ES+): m/z calcd for C28H34N4O3Na [M+Na]+: 497.2512; found 
497.2517. 
N-(2-morpholinoethyl)-1-(2-(2-morpholinoethylcarbamoyl)phenyl)-6-methyl-2,3-
dihydro-1H-pyrrolo[2,3-b]quinoline-4-carboxamide (3h): Yellow solid (15 mg, 44%), 
mp 213-214 oC; 1H NMR (300 MHz, CDCl3):  7.74 (dd, 3J = 7.6 Hz, 4J = 1.5 Hz, 1H, 
C3’-H), 7.56-7.49 (m, 3H, C5-H, C5’-H, C8-H), 7.42-7.35 (m, 2H, C4’-H, C6’-H), 7.30 
(ddd, 3J = 8.7 Hz, 3J = 8.7 Hz, 4J = 1.9 Hz, 1H, C7-H), 7.20 (t, 3J = 5.0 Hz, 1H, 
ArCONH), 6.61 (t, 3J = 5.1 Hz, 1H, PyCONH), 4.06 (t, 3J = 7.8 Hz, 2H, C2-H2), 3.34-
3.69 (m, 4H, 2xCH2(d)), 3.67 (q, 3J = 6.0 Hz, 2H, NHCH2(a)), 3.48-3.43 (m, 4H, 
2xCH2(h)), 3.33-3.26 (m, 4H, C3-H2, NHCH2(e)), 2.65 (t, 3J = 6.0 Hz, 2H, CH2(b)), 
2.57-2.51 (m, 4H, 2xCH2(c)), 2.43 (s, 3H, ArCH3), 2.29-2.22 (m, 6H, CH2(f), 2xCH2(g)); 
13C NMR (75.5 MHz, CDCl3):  168.4 (ArCO), 166.6 (PyCO), 159.7 (C9a), 146.0 (C8a), 
138.8 (C1’), 137.4 (C4), 133.9 (C2’), 133.1 (C6), 131.5 (C5’), 131.0 (C7), 129.9 (C3’), 
126.7 (C8 & C6’), 125.8 (C4’), 123.8 (C5), 123.6 (C3a), 120.9 (C4a), 67.0 (2xCH2(d)), 
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66.9 (2xCH2(h)), 57.2 (CH2(b)), 57.1 (CH2(f)), 53.5 (2xCH2(c)), 53.4 (2xCH2(g)), 52.2 
(C2), 36.2 (CH2(e)), 36.0 (CH2(a)), 25.4 (C3), 21.6 (ArCH3); IR (KBr): max = 3339 (s), 
3246 (s), 3073 (m), 2950 (m), 2858 (m), 2803 (m), 1671 (s) (C=O), 1641 (s) (C=O), 
1599 (m), 1559 (w), 1475 (m), 1439 (m), 1327 (m), 1114 (m) cm-1; LRMS (ES+): m/z 
(%) 595.07 (100) [M+Na]+, 573.12 (10) [M+H]+; HRMS (ES+): m/z calcd for C32H41N6O4 
[M+H]+: 573.3189; found 573.3187. 
Ethyl 2-(7-chloro-4-hydroxy-5-oxo-2,3-dihydrobenzo[f]pyrrole[2,3-b]azepin-1(5H)-
yl)benzoate (4): Yellow solid (142 mg, 40%), mp 144-145 oC; 1H NMR (300 MHz, 
CDCl3):  8.55 (br s, 1H, OH), 8.42 (d, 4J = 2.6 Hz, 1H, C6-H), 7.90 (dd, 3J = 7.7 Hz, 
4J = 1.5 Hz, 1H, C3’-H), 7.58 (ddd, 3J = 7.7 Hz, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, C5’-H), 
7.41 (dd, 3J = 8.9 Hz, 4J = 2.6 Hz, 1H, C8-H), 7.37 (dd, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, 
C4’-H), 7.32 (dd, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, C6’-H), 7.28 (d, 3J = 8.9 Hz, 1H, C9-H), 
4.19 (t, 3J = 7.5 Hz, 2H, C2-H2), 3.96 (q, 3J = 7.2 Hz, 2H, CH2CH3), 3.36 (t, 3J = 7.5 
Hz, 2H, C3-H2), 1.06 (t, 3H, 3J = 7.2 Hz, CH2CH3); 13C NMR (300 MHz, CDCl3):  178.3 
(C5), 167.0 (CO2R), 157.8 (C10a), 153.1 (C4), 148.6 (C9a), 139.1 (C1’), 134.8 (C8), 
134.7 (C9), 132.5 (C5’), 130.5 (C3’), 129.6 (C7 & C2’), 129.1 (C6), 126.5 (C5a), 126.5 
(C4’), 125.4 (C6’), 119.6 (C3a), 61.1 (CO2CH2CH3), 49.8 (C2), 25.3 (C3), 14.1 
(CO2CH2CH3); IR (KBr): max = 3449 (m) (OH), 2977 (m) (CH2), 1717 (s) (C=O), 1675 
(m) (C=O), 1612 (m), 1560 (m), 1459 (s), 1250 (m), 723 (m) (Ar-H) cm-1; LCMS (ES+): 
m/z (%) 419.02 (100) [M+Na]+; HRMS (ES+): m/z calcd for C21H17N2O4NaCl [M+H]+: 
419.0775; found 419.0781; An analytical sample was prepared by recrystallisation 
from toluene; Anal. calcd for C21H17ClN2O4: C, 63.56; H, 4.32; N, 7.06; found: C, 63.28; 
H, 4.00; N, 6.83.  
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